Aldeyra Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALDX Nasdaq 8731 https://www.aldeyra.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aldeyra Therapeutics Inc

Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease - Feb 7th, 2023 12:00 pm
Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit - Jan 12th, 2023 11:37 am
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma - Dec 21st, 2022 12:00 pm
Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication - Dec 13th, 2022 6:37 pm
Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial - Dec 13th, 2022 1:00 pm
Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA - Dec 1st, 2022 1:00 pm
Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease - Nov 29th, 2022 1:00 pm
Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights - Nov 10th, 2022 12:00 pm
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights - Nov 3rd, 2022 12:00 pm
Aldeyra Therapeutics Is a Speculative Stock Worth a Small Position - Nov 2nd, 2022 5:45 pm
Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting - Oct 26th, 2022 12:00 pm
Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision Disorder - Oct 6th, 2022 4:23 pm
Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy - Oct 6th, 2022 11:00 am
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy - Oct 5th, 2022 8:05 pm
Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones - Sep 14th, 2022 12:00 pm
Aldeyra Therapeutics to Participate in Upcoming Investor Conferences - Sep 7th, 2022 12:00 pm
Owning 48% shares,institutional owners seem interested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), - Sep 1st, 2022 10:56 am
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy? - Aug 15th, 2022 1:55 pm
Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript - Aug 7th, 2022 7:00 am
Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights - Aug 5th, 2022 11:00 am